50% OFF SITEWIDE · Orders before 4PM PST ship same day
50% OFF SITEWIDEOrders before 4PM PST ship same day
Science

A Researcher’s Overview of GLP Receptor Agonists

Scientists working in a modern research laboratory
Image: Esculab / Wikimedia Commons (CC0)

Few areas of peptide research have moved as quickly as incretin biology. In twenty years the field has gone from a single hormone, GLP-1, to engineered molecules that activate two or three receptors at once. This overview is a map for researchers entering the area: what the receptors are, how the compound classes differ, and where each of our Metabolic Research compounds fits. For depth on any one class, follow the links to the dedicated articles.

The Incretin System in One Paragraph

When nutrients reach the gut, specialized cells in the intestinal wall release peptide hormones. Two matter most here: glucagon-like peptide-1 (GLP-1), released from L-cells mainly in the lower intestine, and glucose-dependent insulinotropic polypeptide (GIP), released from K-cells higher up. Both travel to the pancreas and amplify insulin release in a glucose-dependent way, a phenomenon called the incretin effect. GLP-1 also slows gastric emptying and acts on incretin-pathway centers in the brain. Both hormones are destroyed within minutes by the enzyme DPP-4, which is why native GLP-1 is nearly useless as a research tool in vivo and why every compound in this class is an engineered analog built to survive.

The Three Receptors

GLP-1 receptor (GLP-1R). A G-protein-coupled receptor expressed on pancreatic beta cells, in the brainstem and hypothalamus, in the heart, and elsewhere. Activation raises cyclic AMP in beta cells and is the best-studied node in the system.

GIP receptor (GIPR). Also a GPCR, expressed on beta cells, in endocrine tissue, bone, and brain. Its biology is more contested; both agonism and antagonism of GIPR have been pursued in metabolic research, and how GIPR signaling adds to GLP-1R activity is an active question.

Glucagon receptor (GCGR). Expressed mainly in the liver. Glucagon raises blood glucose by driving hepatic glucose output, which sounds counterproductive, but it also increases energy expenditure and hepatic fat oxidation. Compounds that add glucagon receptor activity to GLP-1 and GIP activity are designed to capture those effects while the incretin components keep glucose in check.

Single-Receptor Agonists

The first generation of research compounds were GLP-1 receptor agonists: modified versions of GLP-1 or of exendin-4, a related peptide from Gila monster venom, altered to resist DPP-4 and, in later molecules, fitted with a fatty-acid side chain that binds albumin and extends circulating half-life from minutes to days. Preclinical research with this class covers beta-cell function, gastric motility, central incretin-pathway circuits, and cardiovascular and renal models. Our GLP1-S is a long-acting acylated GLP-1 receptor agonist of this type; the class is covered in depth in GLP-1 Receptor Agonists: A Research Overview.

Dual Agonists (GLP-1 + GIP)

The second generation asked whether adding GIP receptor activity to a GLP-1 agonist would produce more than either alone. Dual agonists are single peptides engineered so that one sequence activates both receptors, typically with unbalanced affinity. Preclinical work examines the contribution of each receptor using knockout models and selective antagonists, and studies in endocrine tissue explore GIPR’s role in lipid handling. GLP2-T is a dual GIP/GLP-1 receptor agonist; see Dual Incretin Receptor Agonists.

Triple Agonists (GLP-1 + GIP + Glucagon)

The newest class adds glucagon receptor activity. The research hypothesis is that glucagon’s effect on energy expenditure and liver fat complements the incretin effects on glucose and incretin-pathway. Triple agonists are the most complex molecules in the catalog to design, because the three receptors prefer different sequence features and the balance between them determines the pharmacology. GLP3-R is a triple GLP-1/GIP/glucagon receptor agonist; the class is covered in Triple Incretin Receptor Agonists, and the overall trajectory in The Multi-Agonist Era.

The Amylin Pathway

Amylin is a separate hormone co-secreted with insulin from beta cells, acting on its own receptor family to slow gastric emptying and suppress incretin-pathway through a distinct brainstem pathway. Long-acting amylin analogs are frequently studied alongside GLP-1 class compounds because the two pathways are complementary rather than redundant. Cagrilintide is the amylin analog in our catalog; see Cagrilintide and the Amylin Pathway.

Choosing a Compound for an Experiment

The right choice depends on the question. To isolate GLP-1R signaling, a single agonist is the cleanest tool. To ask what GIPR adds, a dual agonist against a single-agonist control, ideally with a GIPR antagonist arm, is the standard design. Triple agonists suit energy-expenditure and hepatic-lipid endpoints. Whatever the compound, it should arrive with a Certificate of Analysis confirming identity by mass spectrometry and purity by HPLC; these are long, acylated peptides, and synthesis impurities such as deletion sequences can carry different receptor profiles. Our guide to peptide purity explains why this matters more for complex sequences.

Handling Notes

Acylated incretin analogs are prone to aggregation at high concentration and to adsorption onto plastic surfaces at low concentration. Use low-binding tubes, avoid vigorous shaking, and let the lyophilized vial reach room temperature before opening. Reconstituted solutions in bacteriostatic water should be refrigerated and used within a few weeks. See Reconstitution Basics.

All compounds discussed are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.

Research use only. The compounds discussed on this blog are intended for in-vitro laboratory research. Nothing here is medical advice, and none of these materials are for human or veterinary use.

Research Materials

Compounds referenced in this article, each lot third-party tested with a Certificate of Analysis.

GLP1-S Incretin & Metabolic Research GLP1-S View product → GLP2-T Incretin & Metabolic Research GLP2-T View product → GLP3-R Incretin & Metabolic Research GLP3-R View product → Cagrilintide Incretin & Metabolic Research Cagrilintide View product →

Compound data: Cagrilintide data sheet All data sheets →

Keep Reading

Molecular structure comparison of tesamorelin and sermorelin for laboratory research.
November 18, 2026

Tesamorelin vs. Sermorelin: Research Differences

Read →
In vitro receptor signaling research comparing ipamorelin and GHRP-6 pathways.
November 16, 2026

Ipamorelin vs. GHRP-6: Research Differences

Read →
Best Third
November 12, 2026

Best Third-Party Tested Peptides for Research Labs

Read →

← All Articles